Cancer Chemotherapy and Pharmacology

, Volume 66, Issue 5, pp 837–844 | Cite as

Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study

  • Salvatore Del Prete
  • Liliana Montella
  • Michele Caraglia
  • Luigi Maiorino
  • Gregorio Cennamo
  • Vincenzo Montesarchio
  • Guido Piai
  • Antonio Febbraro
  • Luciano Tarantino
  • Elena Capasso
  • Giovannella Palmieri
  • Rosario Guarrasi
  • Maddalena Bianco
  • Rosanna Mamone
  • Clementina Savastano
  • Agata Pisano
  • Bruno Vincenzi
  • Antonietta Sabia
  • Alberto D’Agostino
  • Vincenzo Faiola
  • Raffaele Addeo
Original Article



Advanced hepatocellular carcinoma (HCC) not eligible for local therapies has limited chances of cure. Sorafenib is a multikinase inhibitor with proven activity in advanced HCC. Octreotide is used in this setting with conflicting results. Treatment with sorafenib and long-acting octreotide was tested in advanced HCC to evaluate safety and activity.


Fifty patients with advanced HCC, Child-Pugh A or B, received sorafenib at a dosage of 800 mg/day for 28 days with a following week of rest and long-acting octreotide at a dose of 40 mg, administered every 28 days.


All patients were assessable for safety and efficacy. Sixteen patients out of 50 (34%) were naïve from other therapies, while all the others were previously treated with local and/or systemic treatments. We achieved 5 partial responses (10%), 33 stable diseases (66%) and 12 progressions of disease (24%). Median time to progression was 7.0 months (95% CI, 3.0–10.9 months), and median overall survival was 12 months (95% CI, 6.3–17.4 months). Treatment was well tolerated. Diarrhoea (6%) and hypertension (4%) were the most frequent grade 3 toxicities.


Our data suggest that the combination between sorafenib and long-acting octreotide is active and well tolerated in patients with advanced HCC and could represent another efficacious chance for the management of this population.


Sorafenib Long-acting octreotide Hepatocellular carcinoma 


  1. 1.
    Addeo R, Caraglia M, Del Prete S (2009) Highlights of regional meeting of Italian Southern Oncological Group (GOIM): focus on hepatocellular carcinoma: biological and clinical background, therapeutic guide-lines and perspectives. Expert Opin Investig Drugs 18(3):373–378 (7 Nov 2008, Naples, Italy)CrossRefPubMedGoogle Scholar
  2. 2.
    Caraglia M, Tassone P, Marra M et al (2006) Targeting Raf-kinase: molecular rationales and translational issues. Ann Oncol 17(Suppl 7):vii124–vii127CrossRefPubMedGoogle Scholar
  3. 3.
    Takimoto CH, Awada A (2008) Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol 61:535–548CrossRefPubMedGoogle Scholar
  4. 4.
    Llovet JM, Ricci S, Mazzaferro V et al (2008) SHARP Investigators Study Group Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 24(359):378–390CrossRefGoogle Scholar
  5. 5.
    Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34CrossRefPubMedGoogle Scholar
  6. 6.
    Thomas MB, Abbruzzese JL (2008) Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 23:8093–8108CrossRefGoogle Scholar
  7. 7.
    Llovet JM, Bruix J (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:1312–1327CrossRefPubMedGoogle Scholar
  8. 8.
    Llovet JM, Di Bisceglie A, Bruix J et al (2008) Design and end-points of clinical trials in HCC. J Natl Cancer Inst 100:698–711CrossRefPubMedGoogle Scholar
  9. 9.
    Buscail L, Vernejoul F, Faure P, Torrisani J, Susini C (2002) Regulation of cell proliferation by somatostatin. Ann Endocrinol (Paris) 63:2S13–2S18Google Scholar
  10. 10.
    Hagemeister AL, Sheridan MA (2008) Somatostatin inhibits hepatic growth hormone receptor and insulin-like growth factor I mRNA expression by activating the ERK and PI3K signaling pathways. Am J Physiol Regul Integr Comp Physiol 295:R490–R497PubMedGoogle Scholar
  11. 11.
    Zhao M, Laissue JA, Zimmermann A (1993) “Neuroendocrine” differentiation in hepatocellular carcinomas (HCCs): immunohistochemical reactivity is related to distinct tumor cell types, but not to tumor grade. Histol Histopathol 8:617–626PubMedGoogle Scholar
  12. 12.
    Kouroumalis E, Skordilis P, Thermos K et al (1998) Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study. Gut 42:442–447CrossRefPubMedGoogle Scholar
  13. 13.
    Reubi JC, Zimmermann A, Jonas S et al (1999) Regulatory peptide receptors in human hepatocellular carcinomas. Gut 45:766–774CrossRefPubMedGoogle Scholar
  14. 14.
    Siveke JT, Herberhold C, Folwaczny C (2003) Complete regression of advanced HCC with long acting octreotide. Gut 52:1531CrossRefPubMedGoogle Scholar
  15. 15.
    Samonakis DN, Moschandreas J, Arnaoutis T et al (2002) Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncol Rep 9:903–907PubMedGoogle Scholar
  16. 16.
    Dimitroulopoulos D, Xinopoulos D, Tsamakidis K et al (2002) The role of Sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology 49:1245–1250PubMedGoogle Scholar
  17. 17.
    Raderer M, Hejna MH, Muller C et al (2000) Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol 16:1197–1201PubMedGoogle Scholar
  18. 18.
    Cebon J, Australasian Gastro-Intestinal Trials Group (AGITG) AG000IH Investigators (2006) Somatostatin receptor expression, tumor response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer 95:853–861CrossRefPubMedGoogle Scholar
  19. 19.
    Becker G, Allgaier HP, Olschewski M et al (2007) HECTOR Study Group. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 45:9–15CrossRefPubMedGoogle Scholar
  20. 20.
    Samonakis DN, Notas G, Christodoulakis N, Kouroumalis EA (2008) Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Dig Dis Sci 53:2359–2365CrossRefPubMedGoogle Scholar
  21. 21.
    Montella L, Addeo R, Caraglia M et al (2008) Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience. Oncol Rep 20:385–390PubMedGoogle Scholar
  22. 22.
    Therasse P, Susan G, Arbuck SG et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216CrossRefPubMedGoogle Scholar
  23. 23.
    Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10CrossRefPubMedGoogle Scholar
  24. 24.
    Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRefGoogle Scholar
  25. 25.
    Leung TWT, Patt YZ, Lau W et al (1999) Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5:1676–1681PubMedGoogle Scholar
  26. 26.
    Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard J-Y, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293–4300CrossRefPubMedGoogle Scholar
  27. 27.
    Minami H, Kawada K, Ebi H, Kitagawa K, Kim YI, Araki K, Mukai H, Tahara M, Nakajima H, Nakajima K (2008) Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 99:1492–1498CrossRefPubMedGoogle Scholar
  28. 28.
    Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K (2008) Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99:159–165PubMedGoogle Scholar
  29. 29.
    Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, Hirte HW, Eder JP, Lenz HJ, Schwartz B (2007) Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12:426–437CrossRefPubMedGoogle Scholar
  30. 30.
    Faivre SJ, Raymond E, Douillard J et al (2007) Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 25:149s (Suppl; abstr 3546)Google Scholar
  31. 31.
    Zhu AX (2008) Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 112:250–259CrossRefPubMedGoogle Scholar
  32. 32.
    Philip PA, Mahoney MR, Allmer C et al (2005) Phase II study of erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23:6657–6663CrossRefPubMedGoogle Scholar
  33. 33.
    Thomas MB, Chadha R, Glover K et al (2007) Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110:1059–1066CrossRefPubMedGoogle Scholar
  34. 34.
    Yau T, Chan P, Ng KK et al (2009) Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 115:428–436CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Salvatore Del Prete
    • 1
  • Liliana Montella
    • 1
  • Michele Caraglia
    • 3
  • Luigi Maiorino
    • 2
  • Gregorio Cennamo
    • 1
  • Vincenzo Montesarchio
    • 4
  • Guido Piai
    • 5
  • Antonio Febbraro
    • 6
  • Luciano Tarantino
    • 7
  • Elena Capasso
    • 8
  • Giovannella Palmieri
    • 9
  • Rosario Guarrasi
    • 1
  • Maddalena Bianco
    • 10
  • Rosanna Mamone
    • 11
  • Clementina Savastano
    • 12
  • Agata Pisano
    • 13
  • Bruno Vincenzi
    • 14
  • Antonietta Sabia
    • 15
  • Alberto D’Agostino
    • 16
  • Vincenzo Faiola
    • 1
  • Raffaele Addeo
    • 1
  1. 1.Medical Oncology Unit“San Giovanni di Dio” HospitalFrattaminore, NaplesItaly
  2. 2.Oncology Unit “San Gennaro” HospitalNaplesItaly
  3. 3.Department of Biochemistry and BiophysicsSecond University of NaplesNaplesItaly
  4. 4.Medical Oncology “Cotugno” HospitalNaplesItaly
  5. 5.AO San SebastianoCasertaItaly
  6. 6.Medical Oncology, FatebenefratelliBeneventoItaly
  7. 7.Hepatology and Interventional Ultrasound Unit“San Giovanni di Dio” HospitalFrattaminore, NaplesItaly
  8. 8.Senology UnitArzano, NaplesItaly
  9. 9.Department of Molecular and Clinical Endocrinology and OncologyUniversity “Federico II”NaplesItaly
  10. 10.“San Leonardo” HospitalNaplesItaly
  11. 11.Radiology and Diagnostic Imaging Unit “San Giovanni di Dio” HospitalFrattaminore, NaplesItaly
  12. 12.Medical Oncology “Ruggi d’Aragona” HospitalSalernoItaly
  13. 13.Medical Oncology “S. Maria delle Grazie” HospitalPozzuoli, NaplesItaly
  14. 14.Medical Oncology Campus BiomedicoRomeItaly
  15. 15.Medical Oncology Unit“S. Maria della Pietà”NolaItaly
  16. 16.Surgery Division Unit“Loreto Mare”NaplesItaly

Personalised recommendations